Literature DB >> 10372611

The effects of clozapine on aggression and substance abuse in schizophrenic patients.

J Volavka1.   

Abstract

Aggressive behavior in schizophrenic patients, although infrequent, is a serious problem. It is, however, a relatively common reason for psychiatric admission and poses an increasing threat as more patients are cared for in the community. There is a strong association between substance abuse and violent behavior, and comorbid substance abuse in schizophrenia is also a major problem. The recent introduction of the atypical antipsychotics has brought hope for the pharmacologic management of this group of patients. These newer agents are thought to have antiaggressive effects and perhaps decrease cravings for illicit substances and alcohol. Data from a number of studies have demonstrated that clozapine has antiaggressive effects. A retrospective analysis of 331 schizophrenic patients assessed the effects of clozapine on hostility and aggression. At baseline, 31.4% of patients showed overt physical aggression, and after an average of 47 weeks of treatment with clozapine, this rate had fallen to 1.1%. The antiaggressive effects of clozapine were relatively specific and could not be explained by sedation or general antipsychotic effects. These effects were more pronounced than the effects on other symptoms and were also present in those patients who showed the highest pretreatment levels of hostility and aggression. Clozapine may also be of benefit in the treatment of schizophrenic patients with comorbid substance abuse. After 6 months of treatment with clozapine, substance abusers and nonabusers with schizophrenia or schizoaffective disorder showed similar improvements on measures of psychopathology and psychosocial functioning.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372611

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  The challenge of treating forensic dual diagnosis clients: comment on "integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders".

Authors:  Robert E Drake; Joseph P Morrissey; Kim T Mueser
Journal:  Community Ment Health J       Date:  2006-08-12

Review 2.  Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

Authors:  David C Henderson
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.

Authors:  Ismene L Petrakis; Charla Nich; Elizabeth Ralevski
Journal:  Schizophr Bull       Date:  2006-08-03       Impact factor: 9.306

4.  Mental disorder and violence: is there a relationship beyond substance use?

Authors:  Richard Van Dorn; Jan Volavka; Norman Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-02-26       Impact factor: 4.328

5.  Potential benefits of quetiapine in the treatment of substance dependence disorders.

Authors:  S Pirzada Sattar; Subhash C Bhatia; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 6.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.

Authors:  David C Henderson
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

7.  Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Richard A Van Dorn; Jan Volavka; John Monahan; T Scott Stroup; Joseph P McEvoy; H Ryan Wagner; Eric B Elbogen; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

8.  The neurobiological bases for development of pharmacological treatments of aggressive disorders.

Authors:  Allan Siegel; Suresh Bhatt; Rekha Bhatt; Steven S Zalcman
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

9.  Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia.

Authors:  Al Aditya Khan; Jake Harvey; Samrat Sengupta
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

10.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.